Mid-year doldrums are hitting as multiple pharmaceutical and biotech companies have initiated layoffs across the United States.
The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of the company’s sales team, according to reports.
Teva Pharmaceutical Industries announced a new organization and leadership structure aimed to achieve better commercial focus and drive value creation.
